NORPACE CR (disopyramide phosphate) by Pfizer is mechanisms of action norpace (disopyramide phosphate) is a type 1 antiarrhythmic drug (i. Approved for documented ventricular arrhythmias, such, that and 1 more indications. First approved in 1982.
Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
NORPACE CR (disopyramide phosphate) is a Type IA antiarrhythmic small molecule indicated for documented ventricular arrhythmias. It works by decreasing diastolic depolarization rate, reducing upstroke velocity, and prolonging action potential duration in cardiac cells without affecting adrenergic receptors. The extended-release capsule formulation provides sustained therapeutic levels for chronic arrhythmia management.
Late-stage product with minimal Medicare utilization and high competitive pressure; commercial team likely focused on niche patient retention rather than growth initiatives.
Mechanisms of Action Norpace (disopyramide phosphate) is a Type 1 antiarrhythmic drug (i.e., similar to procainamide and quinidine). In animal studies Norpace decreases the rate of diastolic depolarization (phase 4) in cells with augmented automaticity, decreases the upstroke velocity (phase 0) and…
Worked on NORPACE CR at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on NORPACE CR offers limited career growth potential due to minimal Medicare utilization (1,137 claims), declining market position, and approaching LOE. Roles are primarily focused on defending existing market share in specialized cardiology settings rather than developing new capabilities or strategic initiatives. This is a consolidation/maintenance assignment better suited to experienced brand professionals transitioning to legacy portfolio management.